BridgeBio Pharma, Inc.
BBIO
$76.08
$1.321.77%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 202.39% | 355.17% | 126.26% | 62.46% | 7.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 202.39% | 355.17% | 126.26% | 62.46% | 7.62% |
| Cost of Revenue | 341.89% | 377.48% | 440.54% | 524.54% | 275.17% |
| Gross Profit | 196.87% | 354.09% | 120.67% | 57.33% | 4.66% |
| SG&A Expenses | 61.82% | 78.69% | 83.86% | 93.57% | 91.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.09% | 33.47% | 25.63% | 26.42% | 22.08% |
| Operating Income | 26.00% | 26.38% | 13.04% | -11.69% | -28.38% |
| Income Before Tax | 9.99% | -7.96% | -35.10% | -80.15% | -69.39% |
| Income Tax Expenses | -151.18% | -62.27% | -62.27% | -- | -- |
| Earnings from Continuing Operations | 10.57% | -7.84% | -34.89% | -80.53% | -70.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 18.14% | -5.60% | 5.56% | 15.46% | 11.60% |
| Net Income | 10.89% | -8.02% | -35.31% | -81.63% | -71.08% |
| EBIT | 26.00% | 26.38% | 13.04% | -11.69% | -28.38% |
| EBITDA | 26.16% | 26.54% | 13.07% | -12.01% | -28.92% |
| EPS Basic | 12.83% | -6.09% | -32.90% | -73.58% | -55.29% |
| Normalized Basic EPS | 17.06% | 15.57% | 1.44% | -20.10% | -28.55% |
| EPS Diluted | 12.83% | -6.09% | -32.90% | -73.58% | -55.29% |
| Normalized Diluted EPS | 17.06% | 15.57% | 1.44% | -20.10% | -28.55% |
| Average Basic Shares Outstanding | 2.29% | 1.99% | 2.93% | 4.48% | 7.75% |
| Average Diluted Shares Outstanding | 2.29% | 1.99% | 2.93% | 4.48% | 7.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |